ISPOR - EE705 Cost-Effectiveness Model of Lebrikizumab Compared to Dupilumab in the Treatment of Austrian Patients With Moderate to Severe Atopic Dermatitis

Full Text

EE705 Cost-Effectiveness Model of Lebrikizumab Compared to Dupilumab in the Treatment of Austrian Patients With Moderate to Severe Atopic Dermatitis

Abstract

Authors

B Schwarz L. Sole-Feu B Akmaz

Back to Volume 27, Supplemental Issue 12S

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now